Skip navigation

Collaboration Aims To Advance E2-Based Targeted Protein Degradation

Selection of drug tablets and capsules falling onto the floor.

  Vivek Vishnudas discusses the advantages of E2-based targeted protein degradation.

Published: January 20, 2025  |  Anna MacDonald speaking with Vivek Vishnudas, PhD

In recent years, targeted protein degradation (TPD) has emerged as a promising approach to drug discovery, particularly for diseases with limited treatment options. By targeting previously “undruggable” proteins and harnessing the body’s natural protein degradation pathways, TPD has the potential to develop therapies that go beyond inhibition to actively eliminate disease-driving proteins.
To advance the development of novel degradation technologies, BPGbio has recently partnered with the University of Oxford. The five-year partnership will focus on E2-based protein degradation in oncology and central nervous system (CNS) diseases.
Technology Networks spoke with Dr. Vivek Vishnudas, BPGbio’s chief technology officer and R&D site head, to learn more about the collaboration, the unique advantages of E2-based TPD and its potential to revolutionize treatment for challenging diseases.

About BPM31510
BPM31510IV is BPGbio’s lead candidate in late-stage development for aggressive solid tumors such as glioblastoma multiforme (GBM) and pancreatic cancer. Other topical and oral formulations of the investigational agent are also being developed as a potential treatment for several rare diseases. The compound has demonstrated a tolerable safety profile and shown potential clinical benefits across multiple disease indications. Validated by BPGbio’s NAi Interrogative Biology platform, BPM31510 induces a hallmark shift in the tumor microenvironment (TME) by modulating mitochondrial oxidative phosphorylation in aggressive tumors, leading to cancer cell death. In many mitochondrial diseases, restoring CoQ10 levels can overcome the effect of mutations in genes that lead to mitochondrial dysfunction. BPM31510 has been granted Orphan Drug Designation by the FDA for GBM, pancreatic cancer, and epidermolysis bullosa (EB), as well as Rare Pediatric Disease Designation for primary CoQ10 deficiency and EB.

About BPGbio
BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using bespoke Bayesian AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat disease. For more information, visit www.bpgbio.com.

Media Contact
media@bpgbio.com